The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

The results of a study that identified the pathological mechanism of spinal stenosis and the target gene for treatment ...

Professor Zeng Zexian's team from the Center for Quantitative Biology at the Peking University Academy for Advanced Interdisciplinary Studies, in collaboration with the Peking University-Tsinghua ...

Biology — the science of life, living things and the processes that keep us all running — links up in essential ways with ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Xun Jia, Rajat Mittal, Mihaela Pertea, and Sri Sarma honored for outstanding contributions to engineering and medicine ...

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

When the transatlantic startup AIRNA launched in 2023, it was already years behind other companies that were trying to bring ...